Loading...
•
Dec 31, 2025
MannKind Q4 2025 Earnings Report
MannKind reported strong fourth quarter 2025 revenue growth driven by Furoscix acquisition and continued Afrezza momentum, while reporting a net loss for the quarter.
Key Takeaways
MannKind generated 111955000 in total revenue in Q4 2025, up 46% year-over-year, driven by contributions from Furoscix, Afrezza growth, and higher royalties and collaborations revenue. The company reported a net loss of 15948000 and an operating loss of 7687000 for the quarter.
Total revenue increased 46% year-over-year to 111955000.
Furoscix contributed 23178000 in revenue following the October acquisition.
Afrezza revenue grew 25% year-over-year to 22878000.
Net loss for the quarter was 15948000 compared to net income in the prior year.
Revenue by Segment
Forward Guidance
MannKind highlighted upcoming FDA decisions for Afrezza pediatric and Furoscix ReadyFlow Autoinjector in 2026, along with continued pipeline development and commercial expansion.
Positive Outlook
- Afrezza pediatric PDUFA date set for May 29, 2026.
- Furoscix ReadyFlow Autoinjector PDUFA date set for July 26, 2026.
- Phase 1b topline data for MNKD-201 expected in second half of 2026.
- Initiation of Phase 2 trial for MNKD-201 in IPF.
- Continued revenue momentum across commercial portfolio.
Challenges Ahead
- Reported net loss of 15948000 in Q4 2025.
- Significant increase in SG&A expenses year-over-year.
- Substantial rise in R&D expenses due to pipeline investments.
- Higher interest expenses impacting net results.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...